Highlights from the Systemic Lupus International Collaborating Clinics World Lupus Seminar on Africa
Members of the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) group along with experienced ...
Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...
Baseline factors linked to SLE flares during pregnancy included thrombocytopenia and a history of LN, while antimalarial therapy demonstrated protective effects.
As previously reported, Wedbush initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $35 price target The firm notes its ...
Systemic lupus erythematosus, or lupus, is a complex autoimmune disease in which the immune system mistakenly attacks healthy ...
In December 2024, the National Comprehensive Cancer Network® (NCCN) added AUCATZYL (obecabtagene autoleucel) to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of ...
Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.
Zenas BioPharma (ZBIO) stock rises as Wedbush issues a bullish recommendation based on the company's lead asset obexelimab. Read more here.
A new study sought to identify the frequency and determinants of flares for with people with systemic lupus erythematosus ...
Patients receiving ICIs were associated with a greater risk of developing RA, but lower risks for SLE and SSc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback